Search Results - linan+jiang

37 Results Sort By:
Clonal Spodoptera Frugiperda Cell lines for Enhanced Expression
This technology includes Spodoptera frugiperda (Sf9) cells which were developed to produce recombinant adeno-associated virus. The cells maintain a copy of the vector genome and for production, require infection with a single baculovirus that expresses either structural and nonstructural proteins to produce rAAV, or the non-structural (Rep) proteins...
Published: 8/12/2024   |   Inventor(s): Lina Li, Robert Kotin
Keywords(s):  
Category(s): Application > Research Materials, Application > Therapeutics, Collaboration Sought > Licensing, ResearchProducts > Plasmids/Vectors
Vapor-Deposited Perovskite Film for Photovoltaic Applications
Background Perovskites have been widely considered as promising next-generation materials for future display and solid-state lighting applications. Most perovskite LEDS are mainly produced via solution processing, and over 20% external quantum efficiencies (EQE) in LEDs have been achieved in recent studies. However, vacuum-based deposition has attracted...
Published: 12/14/2023   |   Inventor(s): Jian Li
Keywords(s):  
Category(s): Advanced Materials/Nanotechnology, Semiconductors, Materials & Processes, Physical Science, Manufacturing/Construction/Mechanical, Energy & Power, Alternative Energy
Bio-Engineered Human Prostate Disease Model
This invention is an in vitro human prostate disease model that utilizes microfluidic Organ-on-Chip technology. The model comprises multiple compartments separated by porous membranes, allowing for the co-culturing of essential tissue types involved in prostate diseases. It provides a physiologically relevant environment and enables communication among...
Published: 8/1/2024   |   Inventor(s): Linan Jiang, Cynthia Miranti
Keywords(s):  
Category(s): Technology Classifications > Healthcare Portfolios > Urology, Technology Classifications > Research Tools > Simulators and Modeling Tools
Vapor Deposited and Doped Perovskite Thin Film for LED Applications
Background Perovskites have widely been considered as promising next-generation materials for future display and solid-state lighting applications. Most current perovskite LEDs are produced using solution processing, and over 20% external quantum efficiencies (EQE) in LEDs have been achieved in recent studies. Vacuum-based deposition has also attracted...
Published: 10/1/2024   |   Inventor(s): Tianxin Li, Jian Li, Lin Song Li
Keywords(s): Fuel Cells, Energy, Materials and Electronics
Category(s): Physical Science, Manufacturing/Construction/Mechanical, Advanced Materials/Nanotechnology, Energy & Power
High Affinity Cross Species Single Domain Antibodies Targeting Mesothelin
Abstract: Mesothelin is a cell surface protein that is an excellent target for immunotherapy because of its limited expression on normal tissues and its high expression on many cancers, including mesothelioma, cholangiocarcinoma, pancreatic, ovarian, lung, stomach, bile duct, and triple-negative breast cancer. Researchers at the National Cancer Institute’s...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Ira Pastan, Jessica Hong, Nan Li
Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, HO, MESOTHELIN, Mesothelioma, Recombinant Immunotoxins, RITs
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics
Anti-Glypican 2 Chimeric Antigen Receptor (CAR) Containing CD28 Hinge And Transmembrane Domains For Treating Neuroblastoma
Abstract: Neuroblastomas are the most common extracranial solid tumors in pediatric patients, with 700-800 new cases annually in the United States. Metastatic neuroblastomas have a five-year survival rate of 50% and account for 15% of all pediatric cancer deaths. As such, more effective treatments against high-risk neuroblastomas are urgently needed....
Published: 12/6/2024   |   Inventor(s): Mitchell Ho, Carol Thiele Galetto, Nan Li, Rosa Nguyen, Rosandra Kaplan
Keywords(s): CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotherapy, Medulloblastoma, Neuroblastoma, Retinoblastoma, Small-Cell Lung Cancers
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Human Monoclonal Antibodies Targeting Glypican-2 in Neuroblastoma
Abstract: Neuroblastoma is a rare pediatric cancer that affects one in every hundred thousand children under the age of fifteen in the United States. Current standards of care  are chemotherapy and surgery, followed by stem-cell treatments, radiation and anti-ganglioside antibody therapy, which yield an average three-year survival rate of 10-45%. This...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li, Dimiter Dimitrov
Keywords(s): ADC, ANTIBODY, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-2, GPC2, Immunotoxin, Neuroblastoma, Recombinant Immunotoxin, Rit
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
High Affinity Monoclonal Antibodies Targeting Glypican-2 for Treating Childhood Cancers
Abstract: Neuroblastoma is a rare pediatric cancer with approximately 1,000 new cases arising annually. Current therapies have a less than forty-five percent (45%), three-year survival rate which demonstrate a need for a more effective treatment against this disease. Glypican-2 (GPC2) is a cell surface protein that is preferentially expressed in pediatric...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li, Bryan Fleming
Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, Glypican 2, GPC2, HO, Immunotoxin, Medulloblastoma, Neuroblastoma, Recombinant Immunotoxin, Retinoblastoma, Rit
Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing
New Chimeric Antigen Receptor (CAR) Format for Developing Improved Adoptive Cell Therapies
Abstract: Adoptive cell therapy (ACT) is an attractive new therapeutic approach for treating various cancers. ACT has recently demonstrated a high degree of efficacy when treating patients with hematological malignancies. However, to date, no effective Chimeric Antigen Receptors (CAR) T cell therapy exists for solid tumors. Researchers in the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li, Dan Li
Keywords(s): CANCER, chimeric antigen receptor (CAR), GPC2, GPC3, HO, MESOTHELIN, solid tumor, tumor antigen
Category(s): Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology
High Affinity Monoclonal Antibodies Targeting Glypican-1
Abstract: Pancreatic cancer is the fourth most common cause of death from cancer in the U.S. The overall 5-year survival rate for this disease is 8.5%. Glypican-1 (GPC1), a cell surface heparan sulfate proteoglycan protein that is overexpressed in pancreatic cancer. Due to this preferential expression, GPC1 represents a potential candidate for targeted...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Nan Li
Keywords(s): ADC, Antibody-drug Conjugate, Bispecific Antibody, CAR, chimeric antigen receptor, Glypican-1, GPC1, HO, Immunotoxin, NANOBODY, Pancreatic Cancer, Recombinant Immunotoxin, Rit, Single Domain Antibody
Category(s): Collaboration Sought > Licensing, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Application > Therapeutics
1 2 3 4